STAT
APRIL 20, 2023
The rate of suspected suicide attempts by self-poisoning among children and adults aged 10 to 19 in the U.S. rose by 30% in 2021 compared with pre-pandemic rates, according to a new study published Thursday. The largest surge was among the youngest in that age group — the rate rose 73% for 10- to 12-year-olds and about 49% for 13- to 15-year-olds, compared to 11% for 16- to 19-year-olds.
PharmaVoice
APRIL 20, 2023
The biotech venture capital firm Cure Ventures, led by three industry veterans, raised the inaugural fund in early April and will soon announce its seed companies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 20, 2023
The United States is in poor health. Life expectancy rates have dropped precipitously , and racial health disparities continue, with white adults living more than five and a half years longer than Black adults on average. Child and teen mortality rates have also climbed, particularly among youth of color. Our maternal mortality rate is three times higher than those of other developed countries and is especially elevated for Black women.
The Pharmacist
APRIL 20, 2023
If you go into a community pharmacy, it’s not hard to see the staff being pulled in different directions. Patients are waiting; prescriptions are piling up; delivery drivers need to head out. It’s no easier in other sectors of pharmacy, where most of us are dealing with limited support staff and an increasingly high workload. […] The post ‘We are working in an environment that is setting us up to fail’ appeared first on The Pharmacist.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 20, 2023
President Biden will nominate oncologist Monica Bertagnolli, director of the National Cancer Institute, to lead the National Institutes of Health, three people familiar with the White House’s plans told STAT. Bertagnolli last fall became the first woman to direct NCI, the largest of the NIH’s 27 departments, amid the president’s efforts to relaunch the Cancer Moonshot with the goal of halving cancer deaths and vastly curbing new cases.
BioPharma Dive
APRIL 20, 2023
The company, which previously raised $32 million in Series A funding, joins a growing list of new startups working to develop targeted radiation treatments.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
The Honest Apothecary
APRIL 20, 2023
My Dear Nephew Simon, So great to hear from you again. I’m glad that you found some of the practical advice in the last letter to be helpful. Don’t be too discouraged by the negative cultures being created by other managers in different departments. Focus on your team for now. In time we will talk about how you expand your influence with other stakeholders around the organization.
STAT
APRIL 20, 2023
Talk about AI in medicine often focuses on the most exiting possible innovations like precision diagnostics, clinical prediction systems, and analytics-driven drug discovery. However, with the arrival of large language models like GPT-4, Bard, and LLaMA, there is growing enthusiasm for how AI might reshape the more mundane aspects of clinical practice: clinical documentation and electronic health records.
The Pharmacist
APRIL 20, 2023
An online post that appeared to suggest that a Pharmacy First service could commence from late October this year should not be interpreted as an announcement of the service, government and pharmacy leaders have advised. A notice shared on the National Institute for Health and Care Research (NIHR) website last month seemed to suggest that […] The post Pharmacy First research alert ‘not a guarantee or commitment’ appeared first on The Pharmacist.
STAT
APRIL 20, 2023
How can you be sure a gene therapy is working? What does $11 billion get you in biotech? And who decides which medicines get approved? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Helen Branswell joins us to explain the latest news on Covid-19 boosters and the implications of a Marburg outbreak in Equatorial Guinea.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The Pharmacist
APRIL 20, 2023
Pharmacies have been instrumental in helping people with dementia recover precious memories through music that is meaningful for them, says Rebecca Kennedy, head of communities at the charity Playlist for Life From improving wellbeing to strengthening relationships with families and loved ones, the benefits of music for people living with dementia are multiple.
Pharmaceutical Technology
APRIL 20, 2023
Chinese firm Hasten Biopharmaceutic has raised $315m for business development of its pipeline assets in a financing round co-led by Singapore-based CBC Group and Abu Dhabi sovereign wealth fund Mubadala Investment, The funding round was supported by additional institutional investors. Hasten will also use the proceeds from the round to fund future acquisitions.
The Pharmacist
APRIL 20, 2023
Losing weight, including through a ‘soups and shakes’ diet, can help put type 2 diabetes into remission for at least five years, new landmark research has suggested. A study from Diabetes UK found that nearly a quarter (23%) of participants who took part in a weight management programme were still in remission from type 2 […] The post 'Soups and shakes' diet can have five year impact on diabetes remission appeared first on The Pharmacist.
Pharmaceutical Technology
APRIL 20, 2023
European life sciences venture capital firm Forbion has raised €1.35bn ($1.47bn) across its two new funds. The latest fundraising brings the total funds managed by the company to €3bn ($3.28bn). The Forbion Ventures Fund VI and the Forbion Growth Opportunities Fund II both exceeded their original target sizes. The Forbion Ventures Fund VI’s final close reached the hard cap of €750m ($821.76m), while the Forbion Growth Opportunities Fund II secured €600m ($657.41m).
The Pharmacist
APRIL 20, 2023
The majority of pharmacists have experienced aggression from patients due to medicine supply issues, while almost half of pharmacy teams claim abuse from patients means they are struggling to cope at work, according to the recent Pharmacy Pressures survey from the Pharmaceutical Services Negotiating Committee (PSNC). Of the more than 2,000 pharmacy team members surveyed, […] The post Increase in patient aggression due to medicines shortages appeared first on The Pharmacist.
The Honest Apothecary
APRIL 20, 2023
A gathering of some interesting Pharma and healthcare related news from around the web for Thursday, April 20, 2023 : What Health Systems Could Learn from Starbucks “ Sara Vaezy: Companies like Starbucks and Amazon have done really well at connecting buyers and sellers. In our case, it’s connecting the clinician and the patient, or the system to the consumer with things such as content, information, tools and services.” Reminds of the classic book by Fred Lee, If Disney Ran You
Pharmaceutical Technology
APRIL 20, 2023
Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform. Initially reported in 2011, CircRNA is a naturally occurring class of RNA. CircRNA is resistant to the main cellular RNA degradation mechanisms and therefore has a prolonged half-life compared to linear mRNA.
European Pharmaceutical Review
APRIL 20, 2023
It has been nearly 20 years since a new treatment option has become available [for] newly diagnosed with diffuse large B-cell lymphoma [in the US]” The US Food and Drug Administration (FDA) has approved Polivy ® (polatuzumab vedotin-piiq) in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). “It has been nearly 20 years since a new treatment option has become available to people newly diagnosed with diffuse large B-cell lymphoma,” shared Dr Levi G
Outsourcing Pharma
APRIL 20, 2023
Symptom improvements have been hailed as âvery compellingâ after results from a phase 1 study into a combination of drugs to treat myelofibrosis prove positive.
BioPharma Dive
APRIL 20, 2023
The agency’s decision also converts the biologic drug's approval from accelerated to full, confirming an earlier OK based on tumor responses.
European Pharmaceutical Review
APRIL 20, 2023
Participants with episodic migraines who have had no success with other preventive drugs had an average of four fewer days with migraine per month when given oral atogepant. This is according to results from a preliminary study, of which the abstract will be presented at the American Academy of Neurology’s 75th Annual Meeting held between April 22-27 2023.
Outsourcing Pharma
APRIL 20, 2023
A drug to treat a rare cancer that grows where the esophagus and stomach join has been accepted for review by the China National Medical Products Administration (NMPA).
Orsini Pharmacy
APRIL 20, 2023
Traditional specialty drugs for diseases such as rheumatoid arthritis and multiple sclerosis are best served under an open distribution model where multiple specialty pharmacies can take care of the patient population. However, rare disease specialty pharmacy patients require more support and resources to properly provide continuity of care. Thus, a limited distribution model is needed for each rare disease drug to provide a network of specialty pharmacies that can meet these special requirement
BioPharma Dive
APRIL 20, 2023
With the court victory, the biotech giant could stave off a set of generic competitors for the top-selling drug until 2028.
assurecare
APRIL 20, 2023
Having been a pharmacist for many years, I know that medication adherence has, and continues to be, a huge challenge for healthcare providers. When I owned my pharmacy, a large sign hung on the wall quoting former surgeon general Everett Koop, “ medication only works for those patients that take them. ” This seems like a rather simple concept. However, one of the biggest hurdles I faced over the years was how to get patients to take their routine prescription medications correctly.
Pharma Times
APRIL 20, 2023
IMM-1-104 found to be well tolerated with no dose limiting toxicities or serious adverse events
World Pharma News
APRIL 20, 2023
UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy. The novel study uses immunotherapy. It involves taking a patient's own white blood cells, called T-cells, and modifying them so they can identify and target HIV cells to control the virus without medication.
Pharma Times
APRIL 20, 2023
Brachytherapy is a precise type of radiotherapy that can be used to treat several cancers
Big Molecule Watch
APRIL 20, 2023
On March 31, 2023, Mabwell announced that China’s National Medical Products Administration (NMPA) has approved MAILISHU, a denosumab biosimilar, for the treatment of osteoporosis in postmenopausal women at high risk of fracture. MAILISHU was developed by Mabwell’s wholly owned subsidiary, T-Mab. Mabwell stated that MAILISHU is the world’s second approved biosimilar to denosumab, following the NMPA’s approval of Luye Pharma Group’s BOYOBEI (denosumab) in November 2022.
Pharmaceutical Business Review
APRIL 20, 2023
Currently, the company has six fill finish lines in San Diego, US, that includes a new line which provides various configurations, such as vials, cartridges, and prefilled syringes. Ajinomoto Bio-Pharma stated that the high-speed process is rated to move up to 22,000 syringes an hour through the line, with more than 200 thousand syringes per batch capacity.
Big Molecule Watch
APRIL 20, 2023
On Monday April 17, 2023, Celltrion announced that it has launched VEGZELMA (bevacizumab-adcd, an AVASTIN biosimilar) in the United States for the treatment of several cancers, including metastatic colorectal cancer and breast cancer. As we previously reported , VEGZELMA was approved by the U.S. Food and Drug Administration in September 2022 for use alone or in combination with other agents for treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, meta
Pharmafile
APRIL 20, 2023
US-based rare medicines pharmacy PANTHERx Rare has announced the launch of Cuvrior, a treatment for stable Wilson Disease in adults who are de-coppered and able to take penicillamine.
PharmExec
APRIL 20, 2023
Industry insights on how pharma is faring in tapping new innovations and approaches in digital health.
Pharmafile
APRIL 20, 2023
Eli Lilly and Ivy Tech Community College, Indiana, US, have announced a new scholarship programme, known as Lilly Scholars @ Ivy Tech, which aims to support first generation students, and students who faced socioeconomic barriers, in pursuing credentials in quality, pharmaceutical manufacturing or similar industries.
Express Pharma
APRIL 20, 2023
Will be supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials Dr Reddy’s Laboratories has announced the launch of Treprostinil Injection in the U.S. market. It is a therapeutic equivalent generic version of Remodulin (treprostinil) Injection, approved by U. S. Food and Drug Administration (USFDA). Dr Reddy’s Treprostinil Injection is supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials.
Expert insights. Personalized for you.
256 
Let's personalize your content